Efficacy News and Research

RSS
Cancer patients should find ways to be physically active during and after treatment: New national guidelines

Cancer patients should find ways to be physically active during and after treatment: New national guidelines

FDA approves Prolia for postmenopausal women with osteoporosis

FDA approves Prolia for postmenopausal women with osteoporosis

EpiCept provides update on post-approval commitments requested by EMA for Ceplene

EpiCept provides update on post-approval commitments requested by EMA for Ceplene

Chakra Biotech Sdn Bhd announces name change to Cerca Insights Sdn Bhd

Chakra Biotech Sdn Bhd announces name change to Cerca Insights Sdn Bhd

Mucosis receives € 3M innovation credit line from Dutch Ministry for development of FluGEM influenza vaccine

Mucosis receives € 3M innovation credit line from Dutch Ministry for development of FluGEM influenza vaccine

NewYork-Presbyterian Hospital/Columbia University Medical Center announce presentations at American Urological Association meeting

NewYork-Presbyterian Hospital/Columbia University Medical Center announce presentations at American Urological Association meeting

Celladon announces 6-month data from Phase 2 clinical trial of MYDICAR in advanced heart failure patients

Celladon announces 6-month data from Phase 2 clinical trial of MYDICAR in advanced heart failure patients

Targeted Genetics's partner Celladon presents Phase II trial data with MYDICAR at Heart Failure Congress 2010

Targeted Genetics's partner Celladon presents Phase II trial data with MYDICAR at Heart Failure Congress 2010

Effectiveness of two stroke-prevention procedures vary by age, say researchers

Effectiveness of two stroke-prevention procedures vary by age, say researchers

Clinical abstracts on Urologix' Cooled ThermoTherapy selected for presentation at AUA's GUS meeting

Clinical abstracts on Urologix' Cooled ThermoTherapy selected for presentation at AUA's GUS meeting

Study demonstrates protection against Ebola infection in nonhuman primates using RNAi

Study demonstrates protection against Ebola infection in nonhuman primates using RNAi

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

Previous recommendations on H1N1 pandemic influenza vaccine still stand: SAGE

Previous recommendations on H1N1 pandemic influenza vaccine still stand: SAGE

Age of patients makes a difference in comparing endarteroctomy with carotid stenting for stroke-prevention

Age of patients makes a difference in comparing endarteroctomy with carotid stenting for stroke-prevention

Relevare Pharmaceuticals to present CNSB015 Phase IIa results at international neuropathic pain congress

Relevare Pharmaceuticals to present CNSB015 Phase IIa results at international neuropathic pain congress

Effective infant vaccina­tion against pneumonia needed in sub-Saharan Africa

Effective infant vaccina­tion against pneumonia needed in sub-Saharan Africa

Nymox Pharmaceutical announces symposium and panel discussion on NX-1207 drug for BPH

Nymox Pharmaceutical announces symposium and panel discussion on NX-1207 drug for BPH

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

Biomedical engineering professor receives Transition Career Development Award

Biomedical engineering professor receives Transition Career Development Award

Alimera Sciences provides new data from Iluvien Phase 3 FAME clinical trials for DME

Alimera Sciences provides new data from Iluvien Phase 3 FAME clinical trials for DME

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.